https://www.neurologylive.com/view/phase-1-2-findings-show-highlight-rgx-202-safety-impact-on-key-duchenne-biomarkers
0
0
10/21/23 at 2:04pm
Organization
Neurologylive.com
RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage.
Create an account
or login to join the discussion